期刊文献+

人卵巢癌组织EGFR基因突变的分析 被引量:1

Analysis of EGFR gene mutations in human orarian carcinoma
下载PDF
导出
摘要 目的:研究卵巢癌组织中表皮生长因子受体(epidermal growth factor receptor,EGFR)基因突变的情况,为卵巢癌的靶向治疗提供实验依据。方法:收集南昌大学第二附属医院与江西省肿瘤医院70例卵巢癌组织标本,采用多聚酶链式反应(polymerase chain reaction,PCR)及多聚酶链式反应-限制性内切酶片段长度多态性(PCR-restriction fragment length polymor-phism,PCR-RFLP)分别检测卵巢癌组织EGFR基因是否有第19外显子的缺失及第21外显子的L858R点突变。结果:在70例卵巢癌组织中,PCR未检测到EGFR基因第19外显子缺失突变,PCR-RFLP未检测到第21外显子的L858R点突变。结论:卵巢癌组织EGFR基因中未检测到第19外显子缺失突变和第21外显子的L858R点突变。
出处 《中国肿瘤生物治疗杂志》 CAS CSCD 北大核心 2010年第3期333-335,共3页 Chinese Journal of Cancer Biotherapy
基金 江西省教育厅科学技术研究项目(No.GJJ09120)~~
  • 相关文献

参考文献15

  • 1Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics [J]. CA Cancer J Clin, 1997, 47( 1 ) : 5-27.
  • 2Jorissen RN, Walker F, Pouliot N, Garrett TPJ, Ward CW, Burgess AW. Epidermal growth factor receptor: Mechanisms of activation and signaling [J]. Exp Celt Res, 2003, 284(1) : 31-53.
  • 3Perez Soler R, Chachoua A, Hammond LA, Rowinsky EK, Huberman M, Karp D, et al. Determinants of tumor response and survival with erlotinib in patients with non-small cell lung cancer [J]. J Clin Oncol, 2004, 22(16) : 3238-3247.
  • 4Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer [ J ]. Nat Rev Cancer, 2007, 7(3): 169-181.
  • 5颜笑健,梁立治,曾宗渊,刘继红,袁颂华,魏梅.铂类化疗敏感型卵巢上皮癌复发的影响因素[J].癌症,2005,24(6):751-754. 被引量:14
  • 6Gross ME, Shazer RL, Agus DB. Targeting the HER-kinase axis in cancer [J]. Semin Oneol, 2004, 31 ( 1 ) : 9-20.
  • 7Park S J, Armstrong S, Kim CH, Yu M, Robertson K, Kelley MR, et al. Lack of EGF receptor contributes to drug sensitivity of human germline ceils [J]. Br J Cancer, 2005, 92(2) : 334-341.
  • 8Coley HM, Shotton CF, Ajose-Adeogun A, Modjtahedi H, Thomas H. Receptor tyrosine kinase (RTK) inhibition is effective in chemosensitizing EGFR-expressing drug resistant human ovarian cancer cell lines when used in combination with cytotoxic agents [J]. Biochem Pharmaeol, 2006, 72(8) : 941-948.
  • 9Goffin J, Lacchetti C, Ellis PM, Ung YC, Evans WK. First-line systemic chemotherapy in the treatment of advanced non-small cell lung cancer a systematic [ J ]. J Thoracic Oncol, 2010, 5 (2) : 260 -274.
  • 10张新勇,徐丽艳,汪惠,朱允中,刘喆,岳文涛,唐俊舫,武玮,刘赞,吴羽华,张春彦.EGFR基因突变与酪氨酸激酶抑制剂疗效及预后之间的关系[J].结核病与胸部肿瘤,2008(2):114-119. 被引量:8

二级参考文献17

  • 1Markman M, Hoskins W. Responses to salvage chemotherapy in ovarian cancer: a critical need for precise definitions of the treated population [J]. J Clin Oncol, 1992,10(4) :513-514.
  • 2Rubin SC, Hoskins WJ, Saigo PE, et al. Prognostic factors for recurrence following negative second-look laparoctomy in ovarian caner patients treated with platinum-based chemotherapy[J]. Gynecol Oncol, 1991,42(2): 137-141.
  • 3Vrscaj MU, Rakar S. Neoadjuvant chemotherapy for advanced epithelial ovarian carcinoma: a retrospective case-control study[J]. Eur J Gynaecol Oncol, 2002,23(5):405-410.
  • 4Onda T, Kamura T, Ishizuka N, et al. Feasibility study of neoadjuvant chemotherapy followed by interval cytoreductive surgery for stage Ⅲ/Ⅳovarian, tubal and peritoneal cancers[J]. Jpn J Clin Oncol, 2004,34(1) :43-45.
  • 5Shibata K, Kikkawa F, Mika M, et al. Neoadjuvant chemotherapy for FIGO stage Ⅲ or Ⅳ ovarian cancer: Survival benefit and prognostic factors [J]. Int J Gynecol Cancer,2003,13 (5): 587-592.
  • 6Markman M. Current status of intraperitoneal therapy for ovarian cancer [J]. Curr Opin Obstet Gynecol, 1993,5(1):99-104.
  • 7Hatae M, Onishi Y, Nakamura T, et al. Neoadjuvant chemotherapy for advanced epithelial ovarian cancer [J]. Gan To Kagaku Ryoho, 2001,28(12): 1833-1837.
  • 8Vergote I. Role of surgery in ovarian cancer: an update [J].Acta Chir Belg, 2004,104 (3): 246-256.
  • 9Coukos G, Rubin SC. Early ovarian cancer [J]. Curr Treat Options Oncol, 2000,1 (2): 129-137.
  • 10Piccart MJ, Bertelsen K, Stuart G, et al. Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer [J]. Int J Gynecol Cancer, 2003,13(Suppl 2):144-148.

共引文献20

同被引文献17

  • 1刘俊丽,陈元,蔡煜,张敏.选择性EGFR酪氨酸激酶抑制剂吉非替尼对宫颈癌离体细胞的放射增敏作用[J].肿瘤防治研究,2007,34(7):480-482. 被引量:8
  • 2KARIMI ZM,BEHTASH N,CHITI Z. Cervical cancer and HPV vaccines in developing countries[J].Asian Pacific Journal of Cancer Prevention,2009,(06):969-974.
  • 3BENEDET JL,OD1CINO F,MAISONNEUVE p. Carcinoma of the cervix uteri[J].International Journal of Gynecology and Obstetrics,2003,(Suppl 1):41-78.
  • 4KESIC V. Management of cervical cancer[J].European Journal of Surgical Oncology,2006,(08):832-837.doi:10.1016/j.ejso.2006.03.037.
  • 5CADRON I,VAN GORP T,AMANT F. Chemotherapy for recurrent cervical cancer[J].Gynecologic Oncology,2007,(Suppl 1):S113-S118.
  • 6MENDELSOHN J,BASELGA J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer[J].Journal of Clinical Oncology,2003,(14):2787-2799.
  • 7GRIDELLI C,DE MARINIS F,DIMAIO M. Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation:Review of the evidence[J].Lung Cancer,2011,(03):249-257.
  • 8PAEZ JG,JANNE PA,LEE JC. EGFR mutations in lung cancer:correlation with clinical response to gefitinib therapy[J].Science,2004,(5676):1497-1500.
  • 9YOSHIDA K,YATABE Y,PARK J. Clinical outcomes of advanced non-small cell lung cancer patients screened for epidermal growth factor receptor gene mutations[J].Journal of Cancer Research and Clinical Oncology,2010,(04):527-535.
  • 10GONCALVES A,FABBRO M,LHOMME C. A phase Ⅱ trial to evaluate gefitinib as second-or third-line treatment in patients with recurring locoregionally advanced or metastatic cervical cancer[J].Gynecologic Oncology,2008,(01):42-46.

引证文献1

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部